Balasubrahmanyam Budda
Overview
Explore the profile of Balasubrahmanyam Budda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
75
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Long H, Simmons A, Mayorga A, Burgess B, Nguyen T, Budda B, et al.
Alzheimers Res Ther
. 2024 Oct;
16(1):235.
PMID: 39444037
Background: Variants of the gene triggering receptor expressed on myeloid cells-2 (TREM2) increase the risk of Alzheimer's disease (AD) and other neurodegenerative disorders. Signaling by TREM2, an innate immune receptor...
2.
Ward M, Carter L, Huang J, Maslyar D, Budda B, Paul R, et al.
Alzheimers Dement (N Y)
. 2024 Feb;
10(1):e12452.
PMID: 38356474
Introduction: Heterozygous mutations in the gene lead to reduced progranulin (PGRN) levels in plasma and cerebrospinal fluid (CSF) and are causative of frontotemporal dementia (FTD) with > 90% penetrance. Latozinemab...
3.
Chen N, Kassir N, Laadem A, Giuseppi A, Shetty J, Maxwell S, et al.
J Clin Pharmacol
. 2020 Jul;
61(1):52-63.
PMID: 32696522
β-Thalassemia is an inherited blood disorder resulting from defects in hemoglobin production, leading to premature death of red blood cells (RBCs) or their precursors. Patients with transfusion-dependent β-thalassemia often need...
4.
Chen N, Kassir N, Laadem A, Maxwell S, Sriraman P, Giuseppi A, et al.
CPT Pharmacometrics Syst Pharmacol
. 2020 Jul;
9(7):395-404.
PMID: 32602651
Luspatercept is a recombinant fusion protein that enhances late-stage erythroid maturation. This report describes the population pharmacokinetics and exposure-response relationship of luspatercept in 260 patients with anemia due to myelodysplastic...
5.
Pal D, Kwatra D, Minocha M, Paturi D, Budda B, Mitra A
Life Sci
. 2010 Oct;
88(21-22):959-71.
PMID: 20932495
Multidrug regimens and corresponding drug interactions cause many adverse reactions and treatment failures. Drug efflux transporters: P-gp, MRP, BCRP in conjunction with metabolizing enzymes (CYPs) are major factors in such...
6.
Katragadda S, Budda B, Anand B, Mitra A
Expert Opin Drug Deliv
. 2005 Nov;
2(4):683-705.
PMID: 16296794
The impact of efflux pumps and metabolic enzymes on the therapeutic activity of various drugs has been well established. The presence of efflux pumps on various tissues and tumours has...